早期启动生物疗法以预防严重喘进展
Alessandra Tomasello1,2, Alida Benfante1, Stefania Principe3
1Division of Respiratory Medicine, PROMISE Department, "Paolo Giaccone" University Hospital, University of Palermo, 90127 Palermo, Italy.
对喘的早期生物治疗,以血中乙氨基基细胞计数和分数呼出的氧化 (FeNO) 等生物标志物为指导,可以预防严重的疾病进展并改善结果. 这种方法从反应性转向主动性喘管理.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 过敏 过敏是一种过敏.
背景情况:
- 喘是一种慢性,异质的炎症性疾病,可以默默地进展.
- 目前的指导方针建议在治疗失败和频繁恶化后对生物疗法进行反应性治疗.
- 这种反应性方法可能导致不可逆转的气道改造,限制生物治疗的有效性.
研究的目的:
- 倡导在喘管理中从基于严重程度的转向基于风险的治疗策略.
- 促进早期启动以生物标志物为指导的生物疗法.
- 重新定义喘治疗升级标准,并为症状不恶化的患者探索生物药物.
主要方法:
- 审查目前的喘治疗指南和生物疗法的作用.
- 重点是以生物标志物为指导的治疗启动,包括血液中乙氨基酸的数量和部分呼出的氧化 (FeNO).
- 关于重新评估升级标准和设计早期干预临床试验的建议.
主要成果:
- 早期以生物标志物为指导的生物疗法可以预防严重喘的进展.
- 积极的干预可能会提高缓解率并减少长期发病率.
- 早期识别持续性炎症和进展风险至关重要.
结论:
- 使用生物标志物的主动,基于风险的方法可以改变喘的轨迹.
- 早期使用生物药物的干预可以防止不可逆转的气道损伤.
- 改变治疗策略可以导致持续控制喘并减少患者负担.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
